Royalty Pharma to provide R&D investment of up to $250 million for Biogen's litifilimab, a potential first-in-class biologic in Phase 3 development for the treatment of lupus. NEW ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback